Silo Pharma, Inc. (SILO) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
애널리스트 추정 주당순이익(EPS) $-0.56 및 매출 $0.00B 다음 회계연도.
주당순이익(EPS) 실적 추이: 2024: 실적 $-1.19 vs 추정 $-0.56 (하회 -112.5%). 2025: 실적 $-0.50 vs 추정 $-0.70 (상회 +28.6%). 애널리스트 정확도: 54%.
EPS 전망 — SILO
54%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.19
vs Est –$0.56
▼ 52.9% off
2025
Actual –$0.50
vs Est –$0.70
▲ 40.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
매출 전망 — SILO
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▲ 0.1% off
2025
Actual $0.000B
vs Est $0.000B
▲ 0.1% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
